Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224698 · ClinicalTrials.gov registry record · Phase 2
Inhaled Cannabis for Treatment of PTSD
A Phase 2 study, sponsored by Multidisciplinary Association for Psychedelic Studies.
- Not yet
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT07224698: Clinical Trial Phase 2 study, sponsored by Multidisciplinary Association for Psychedelic Studies.
NCT07224698 is a Phase 2 study that has not yet begun recruiting, run by Multidisciplinary Association for Psychedelic Studies. The registered enrollment target is 320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224698, a Phase 2 study, has not yet begun recruiting, sponsored by Multidisciplinary Association for Psychedelic Studies.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.
Interventions
- DRUG Placebo cannabis
- DRUG High THC Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
What is known before NCT07224698 opens enrollment
NCT07224698 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo cannabis is the first listed.
NCT07224698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07224698 about?
NCT07224698 is a clinical study titled "Inhaled Cannabis for Treatment of PTSD". The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a paralle...
What is the current status of trial NCT07224698?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2026-02-01. Estimated completion is 2027-11-30.
What interventions are being tested in trial NCT07224698?
The interventions under investigation include: Placebo cannabis (DRUG), High THC Cannabis (DRUG).
Who is sponsoring clinical trial NCT07224698?
This trial is sponsored by Multidisciplinary Association for Psychedelic Studies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07224698's enrollment target sits among peer trials
320 152nd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI